Comparative Activities of TR-700 (Torezolid) against Staphylococcal Blood Isolates Collected in Spain | Zendy

Carmen Betriú | Zendy; Gracia Morales | Zendy; Iciar Rodríguez-Avial | Zendy; Esther Culebras | Zendy; María Teresa Martín-Gómez | Zendy; Fátima López | Zendy; Juan J. Picazo | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Comparative Activities of TR-700 (Torezolid) against Staphylococcal Blood Isolates Collected in Spain

Author(s) -

Carmen Betriú,

Gracia Morales,

Iciar Rodríguez-Avial,

Esther Culebras,

María Teresa Martín-Gómez,

Fátima López,

Juan J. Picazo

Publication year - 2010

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01653-09

Subject(s) - linezolid , daptomycin , staphylococcus aureus , microbiology and biotechnology , vancomycin , potency , methicillin resistant staphylococcus aureus , micrococcaceae , antibiotics , staphylococcus , antibacterial agent , medicine , in vitro , biology , bacteria , biochemistry , genetics

The in vitro activity of TR-700 (torezolid) was evaluated against a collection of 660 staphylococcal blood isolates. TR-700 showed excellent activity against all the staphylococci tested. The MIC(50) and MIC(90) values of TR-700, linezolid, daptomycin, and vancomycin against methicillin-resistant Staphylococcus aureus (MRSA) isolates were 0.25 and 0.5, 2 and 4, 0.5 and 0.5, and 1 and 2 microg/ml, respectively. TR-700 demonstrated greater in vitro potency than linezolid against staphylococci, including linezolid-resistant and vancomycin-nonsusceptible strains, and was 32-fold more active than linezolid against the seven cfr-positive MRSA strains tested.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research